Related references
Note: Only part of the references are listed.Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia
Jitesh D. Kawedia et al.
BLOOD (2012)
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia
Jitesh D. Kawedia et al.
BLOOD (2011)
Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials
Andrea Willer et al.
BLOOD (2011)
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia
Jun J. Yang et al.
NATURE GENETICS (2011)
Genetic Variations in GRIA1 on Chromosome 5q33 Related to Asparaginase Hypersensitivity
S-H Chen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
A Mouse Model for Glucocorticoid-Induced Osteonecrosis: Effect of a Steroid Holiday
Lei Yang et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2009)
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
Ching-Hon Pui et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Impaired dexamethasone-related increase of anticoagulants is associated with the development of osteonecrosis in childhood acute lymphoblastic leukemia
Mariel L. te Winkel et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia
Lei Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Allergic reactions to E-coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia -: A Children's Oncology Group study
Pierre Wacker et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2007)
Meta-analysis: Diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis
Kunihiro Nishimura et al.
ANNALS OF INTERNAL MEDICINE (2007)
The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia
Beata Zalewska-Szewczyk et al.
LEUKEMIA & LYMPHOMA (2007)
Osteonecrosis in children and adolescents with cancer - An adverse effect of systemic therapy
Alessandra Sala et al.
EUROPEAN JOURNAL OF CANCER (2007)
Osteonecrosis:: A treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) -: Experiences from trial ALL-BFM 95
B Bürger et al.
PEDIATRIC BLOOD & CANCER (2005)
D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism - A systematic review
PD Stein et al.
ANNALS OF INTERNAL MEDICINE (2004)
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia - Children's Cancer Group Study CCG-1961
EH Panosyan et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2004)
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia
MV Relling et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients
B Wang et al.
LEUKEMIA (2003)
Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing
DH Solomon et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2002)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study
VI Avramis et al.
BLOOD (2002)
Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the children's cancer group
LA Mattano et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia
B Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia
MH Woo et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
